Rodent Tumor Model
Rodent Tumor Model - Related Videos
10:04
Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
0 Views •
Cited by 28 •
2018
We describe a protocol for preclinical in vivo tracking of cancer metastasis. It is based on a radionuclide-fluorescence reporter combining the sodium iodide symporter, detected by non-invasive [18F]tetrafluoroborate-PET, and a fluorescent protein for streamlined ex vivo confirmation. The method is applicable for preclinical in vivo cell tracking beyond tumor biology.
10:29
Principles of Rodent Surgery for the New Surgeon
0 Views •
Cited by 56 •
2011
Before attempting surgery, a new surgeon should have training in basic surgical techniques and concepts. This article will present basic surgical considerations with an emphasis on rodents.
09:40
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
0 Views •
Cited by 35 •
2016
Pulmonary arterial hypertension (PAH) is a disease of pulmonary arterioles that leads to their obliteration and the development of right ventricular failure. Rodent models of PAH are critical in understanding the pathophysiology of PAH. Here we demonstrate hemodynamic characterization, with right heart catheterization and echocardiography, in the mouse and rat.
07:49
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
0 Views •
Cited by 15 •
2015
This protocol describes a method for the detailed evaluation of leukocyte subsets within the tumor microenvironment in a mouse tumor model. Chemerin-expressing B16 melanoma cells were implanted subcutaneously into syngeneic mice. Cells from the tumor microenvironment were then stained and analyzed by flow cytometry, allowing for detailed leukocyte subset analyses.
07:58
Preparing Undercut Model of Posttraumatic Epileptogenesis in Rodents
0 Views •
Cited by 14 •
2011
Partially isolated cortex (“undercut”) is an efficient animal model of posttraumatic epileptogenesis. Here we demonstrate how to make a novel surgical device and use it to make more precise and consistent lesions to generate this model.
FAQs
Model selection determines which cancer features can be examined. Genetically engineered animals can represent tumor-associated genetic changes, whereas chemical induction or transplantation creates different experimental routes to tumor formation. Immune-competent and immune-deficient hosts also alter the biological setting, making host immune status an important variable when interpreting tumor growth or treatment response.
Monitoring tumor growth, invasion, metastasis, and treatment response allows investigators to separate effects on tumor behavior from effects on therapy performance. These observations can expose mechanisms of progression and show whether an intervention changes a measurable cancer outcome under controlled biological conditions. The resulting evidence supports preclinical decisions, while remaining specific to the model used.
Rodent findings require careful interpretation because the experimental system reproduces only selected aspects of human cancer biology. Differences between rodent and human biology may affect tumor behavior, therapeutic response, or treatment toxicity. Consequently, a result can be informative about a mechanism or preclinical outcome without guaranteeing that the same effect will occur in human research.
Investigators can establish tumors through genetic engineering, chemical induction, or transplantation of tumor cells. The choice sets the biological context in which tumor development and therapy are studied. Researchers may also work in immune-competent or immune-deficient animals, depending on the defined conditions needed to examine tumor behavior, treatment response, or host-related effects.
These systems provide a controlled setting for evaluating anticancer drugs, radiation, and immunotherapies. Researchers can monitor tumor growth and responses to treatment, then compare outcomes under defined biological conditions. This approach helps determine whether an intervention affects cancer-related behavior and can contribute evidence for preclinical decisions before results are considered alongside the limitations of rodent-human translation.
Beyond tumor size or progression, these systems can be used to study biomarkers and treatment toxicity. Biomarkers may help connect a biological process with tumor behavior or therapeutic response, while toxicity assessment addresses unwanted effects under the same experimental conditions. Considering efficacy and toxicity together gives cancer researchers a broader basis for judging an intervention's preclinical potential.